In Search of Better Algorithms for Treatment of Crohn DiseaseJuly 16th 2020
Wide variation in treatment patterns for Crohn disease is attributable to failures to translate evidence uniformly and cost barriers. Authors of a new report have formulated algorithms to help reduce heterogeneity in treatment of patients.
Use of Infliximab Biosimilar in Medicare Population Is Low but GrowingJuly 7th 2020
Slow growth of use of biosimilar infliximab in a Medicare fee-for-service population suggests lingering hesitancy on the part of gastroenterologists and patients, particularly when it comes to extrapolation to off-label uses, according to a new study.